Schizophrenia (Heidelberg, Germany)最新文献

{"title":"Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.","authors":"Nora Penzel, Pablo Polosecki, Jean Addington, Celso Arango, Ameneh Asgari-Targhi, Tashrif Billah, Sylvain Bouix, Monica E Calkins, Dylan E Campbell, Tyrone D Cannon, Eduardo Castro, Kang Ik K Cho, Michael J Coleman, Cheryl M Corcoran, Dominic Dwyer, Sophia Frangou, Paolo Fusar-Poli, Robert J Glynn, Anastasia Haidar, Michael P Harms, Grace R Jacobs, Joseph Kambeitz, Tina Kapur, Sinead M Kelly, Nikolaos Koutsouleris, K R Abhinandan, Saryet Kucukemiroglu, Jun Soo Kwon, Kathryn E Lewandowski, Qingqin S Li, Valentina Mantua, Daniel H Mathalon, Vijay A Mittal, Spero Nicholas, Gahan J Pandina, Diana O Perkins, Andrew Potter, Abraham Reichenberg, Jenna Reinen, Michael S Sand, Johanna Seitz-Holland, Jai L Shah, Vairavan Srinivasan, Agrima Srivastava, William S Stone, John Torous, Mark G Vangel, Jijun Wang, Phillip Wolff, Beier Yao, Alan Anticevic, Daniel H Wolf, Hao Zhu, Carrie E Bearden, Patrick D McGorry, Barnaby Nelson, John M Kane, Scott W Woods, René S Kahn, Martha E Shenton, Guillermo Cecchi, Ofer Pasternak","doi":"10.1038/s41537-025-00561-w","DOIUrl":"10.1038/s41537-025-00561-w","url":null,"abstract":"<p><p>The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project assesses a large sample of individuals at clinical high-risk for developing psychosis (CHR) and community controls. Subjects are enrolled in 43 sites across 5 continents. The assessments include domains similar to those acquired in previous CHR studies along with novel domains that are collected longitudinally across a period of 2 years. In parallel with the data acquisition, multidisciplinary teams of experts have been working to formulate the data analysis strategy for the AMP SCZ project. Here, we describe the key principles for the data analysis. The primary AMP SCZ analysis aim is to use baseline clinical assessments and multimodal biomarkers to predict clinical endpoints of CHR individuals. These endpoints are defined for the AMP SCZ study as transition to psychosis (i.e., conversion), remission from CHR syndrome, and persistent CHR syndrome (non-conversion/non-remission) obtained at one year and two years after baseline assessment. The secondary aim is to use longitudinal clinical assessments and multimodal biomarkers from all time points to identify clinical trajectories that differentiate subgroups of CHR individuals. The design of the analysis plan is informed by reviewing legacy data and the analytic approaches from similar international CHR studies. In addition, we consider properties of the newly acquired data that are distinct from the available legacy data. Legacy data are used to assist analysis pipeline building, perform benchmark experiments, quantify clinical concepts and to make design decisions meant to overcome the challenges encountered in previous studies. We present the analytic design of the AMP SCZ project, mitigation strategies to address challenges related to the analysis plan, provide rationales for key decisions, and present examples of how the legacy data have been used to support design decisions for the analysis of the multimodal and longitudinal data. Watch Prof. Ofer Pasternak discuss his work and this article: https://vimeo.com/1023394132?share=copy#t=0 .</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"53"},"PeriodicalIF":3.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.","authors":"Michael P Harms, Kang-Ik K Cho, Alan Anticevic, Nicolas R Bolo, Sylvain Bouix, Dylan Campbell, Tyrone D Cannon, Guillermo Cecchi, Mathias Goncalves, Anastasia Haidar, Dylan E Hughes, Igor Izyurov, Omar John, Tina Kapur, Nicholas Kim, Elana Kotler, Marek Kubicki, Joshua M Kuperman, Kristen Laulette, Ulrich Lindberg, Christopher Markiewicz, Lipeng Ning, Russell A Poldrack, Yogesh Rathi, Paul A Romo, Zailyn Tamayo, Cassandra Wannan, Alana Wickham, Walid Yassin, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J K Breitborde, Matthew R Broome, Kristin S Cadenhead, Monica E Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M Corcoran, Barbara A Cornblatt, Covadonga M Diaz-Caneja, Lauren M Ellman, Paolo Fusar-Poli, Pablo A Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H Mathalon, Vijay A Mittal, Merete Nordentoft, Godfrey D Pearlson, Jesus Perez, Diana O Perkins, Albert R Powers, Jack Rogers, Fred W Sabb, Jason Schiffman, Jai L Shah, Steven M Silverstein, Stefan Smesny, William S Stone, Gregory P Strauss, Judy L Thompson, Rachel Upthegrove, Swapna K Verma, Jijun Wang, Daniel H Wolf, Rene S Kahn, John M Kane, Patrick D McGorry, Barnaby Nelson, Scott W Woods, Martha E Shenton, Stephen J Wood, Carrie E Bearden, Ofer Pasternak","doi":"10.1038/s41537-025-00581-6","DOIUrl":"10.1038/s41537-025-00581-6","url":null,"abstract":"<p><p>Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or predictive biomarkers that can enhance our ability to forecast clinical outcomes. To date, most studies involving MRI in CHR are likely not sufficiently powered to generate robust and generalizable neuroimaging results. Here, we describe the prospective, advanced, and modern neuroimaging protocol that was implemented in a complex multi-site, multi-vendor environment, as part of the large-scale Accelerating Medicines Partnership® Schizophrenia Program (AMP® SCZ), including the rationale for various choices. This protocol includes T1- and T2-weighted structural scans, resting-state fMRI, and diffusion-weighted imaging collected at two time points, approximately 2 months apart. We also present preliminary variance component analyses of several measures, such as signal- and contrast-to-noise ratio (SNR/CNR) and spatial smoothness, to provide quantitative data on the relative percentages of participant, site, and platform (i.e., scanner model) variance. Site-related variance is generally small (typically <10%). For the SNR/CNR measures from the structural and fMRI scans, participant variance is the largest component (as desired; 40-76%). However, for SNR/CNR in the diffusion scans, there is substantial platform-related variance (>55%) due to differences in the diffusion imaging hardware capabilities of the different scanners. Also, spatial smoothness generally has a large platform-related variance due to inherent, difficult to control, differences between vendors in their acquisitions and reconstructions. These results illustrate some of the factors that will need to be considered in analyses of the AMP SCZ neuroimaging data, which will be the largest CHR cohort to date.Watch Dr. Harms discuss this article at https://vimeo.com/1059777228?share=copy#t=0 .</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"52"},"PeriodicalIF":3.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143774579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COSMIN review of the PANSS Marder factor solution and other factor models in people with schizophrenia.","authors":"Maximilian Roithmeier, Simon Geck, Markus Bühner, Sophia Wehr, Lucia Weigel, Josef Priller, John M Davis, Stefan Leucht","doi":"10.1038/s41537-025-00600-6","DOIUrl":"10.1038/s41537-025-00600-6","url":null,"abstract":"<p><p>The Positive and Negative Syndrome Scale (PANSS) is widely used to assess schizophrenia symptoms. Initially designed with three subscales, Marder et al.´s 5-factor-Model (M5M) first proposed in 1997 has been frequently used in treatment trials, but it has never been systematically reviewed for its measurement properties. We utilized the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guideline for systematic reviews and meta-analytical procedures to assess the psychometric properties of the M5M-PANSS. COSMIN comprises several steps: literature search, risk-of-bias assessments, assessing the updated criteria for good measurement properties, feasibility aspects and grading the quality of the evidence. We further assessed the goodness of fit of other PANSS factor models. We included 95 publications. The M5M-PANSS showed good construct validity, but \"insufficient\" structural validity. Evidence of other COSMIN domains is largely lacking. Among the multiple (73) factor solutions examined with confirmatory methods, several other 5-factor solutions had better model fit. According to COSMIN rules the M5M should not be recommended for use. Other five-factor models such as the one proposed by Wallwork et al.¹ warrant further evaluation. Nevertheless, the factor composition of the M5M and these other models was relatively similar, so previously published results should not be disregarded.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"51"},"PeriodicalIF":3.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External stress, formaldehyde, and schizophrenia: a new mouse model for mental illness research.","authors":"Junhao Cheng, Zihui Sun, Hao Zhang, Danrui Zhao, Panpan Wang, Haishu Chen, Wanjia Lyv, Qiangfeng Deng, Yuanyu Fu, Xingzhou Lyv, Tingting Gao, Jinan Xu, Feiyan Zhou, Yiqing Wu, Xu Yang, Ping Ma, Zhiqian Tong","doi":"10.1038/s41537-025-00603-3","DOIUrl":"10.1038/s41537-025-00603-3","url":null,"abstract":"<p><p>Although MK801-induced NMDA receptor (NMDAR) hypofunction mimics schizophrenia symptoms, the exact factors causing NMDAR inhibition are unknown. Unexpectedly, external stress elicits formaldehyde (FA) generation; FA can induce depression and cognitive impairments by blocking NMDARs. This study explores using FA injection to establish a schizophrenia-like model in mice. Here, we reported that external stress-derived FA induces schizophrenia-like behaviors. Four experimental methods were used to induce schizophrenia-like symptoms in wild-type mice: double electrode stimulation of the ventral tegmental area (VTA), microinjection of FA or tetrahydroisoquinoline (TIQ) into the VTA, and intraperitoneal injection of MK801. Then the metabolic levels of FA and dopamine (DA) in the prefrontal cortex (PFC) and VTA were quantified using ELISA kits. We found that external stress-electrical stimulation via VTA caused schizophrenia-like behaviors, including despairing behavior as measured by the tail suspension test, anhedonia as evaluated by the sucrose preference test, stereotypical behavior as assessed by the marble burying test (MBT), anxiety-like behavior as measured by the open-field test and memory deficit as detected by the Y-maze. These behaviors correlated with increased DA and TIQ levels in the VTA and decreased DA levels in the PFC. High-resolution mass spectrometry (HRMS) and high-performance liquid chromatography (HPLC) confirmed TIQ formation from FA and DA. Furthermore, injecting TIQ into the VTA induced schizophrenia-like symptoms in mice, marked by higher FA and lower DA levels in the PFC than control mice. Strikingly, injecting FA into the VTA as well as administering MK-801 induced schizophrenia-like behaviors associated with reduced DA levels and low activity of tyrosine hydroxylase (TH) and monoamine oxidase (MAO) in the PFC. Hence, microinfusion of FA into the VTA can be used to prepare schizophrenia-like changes mouse model, suggesting that stress-derived FA may act as an endogenous trigger of schizophrenia-like changes.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"50"},"PeriodicalIF":3.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.","authors":"Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders, Kate Buccilli, Ricardo E Carrión, Rolando I Castillo-Passi, Kang Ik K Cho, Kota Chin, Michael J Coleman, Beau-Luke Colton, Sebastián Corral, Dominic Dwyer, Kristina Ballestad Gundersen, Ruben C Gur, Gil D Hoftman, Grace R Jacobs, Sinead Kelly, Kathryn E Lewandowski, Patricia J Marcy, Priya Matneja, Danielle McLaughlin, Angela R Nunez, Setari Parsa, Nora Penzel, Susan Ray, Jenna M Reinen, Kosha Ruparel, Michael S Sand, Gennarina Santorelli, Johanna Seitz-Holland, Jessica Spark, Zailyn Tamayo, Andrew Thompson, Sophie Tod, Cassandra M J Wannan, Alana Wickham, Stephen J Wood, Eirini Zoupou, Jean Addington, Alan Anticevic, Celso Arango, Nicholas J K Breitborde, Matthew R Broome, Kristin S Cadenhead, Monica E Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M Corcoran, Barbara A Cornblatt, Lauren M Ellman, Paolo Fusar-Poli, Pablo A Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Covadonga M Diaz-Caneja, Daniel H Mathalon, Vijay A Mittal, Merete Nordentoft, Godfrey D Pearlson, Diana O Perkins, Jesus Perez, Albert R Powers, Jack Rogers, Fred W Sabb, Jason Schiffman, Jai L Shah, Steven M Silverstein, Stefan Smesny, Gregory P Strauss, Judy L Thompson, Rachel Upthegrove, Swapna K Verma, Jijun Wang, Daniel H Wolf, Ofer Pasternak, Sylvain Bouix, Patrick D McGorry, John M Kane, Rene S Kahn, Carrie E Bearden, Martha E Shenton, Scott W Woods, Barnaby Nelson, William S Stone","doi":"10.1038/s41537-025-00578-1","DOIUrl":"10.1038/s41537-025-00578-1","url":null,"abstract":"<p><p>Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"49"},"PeriodicalIF":3.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resting-state EEG and MEG gamma frequencies in schizophrenia: a systematic review and exploratory power-spectrum metanalysis.","authors":"Marco De Pieri, Michel Sabe, Vincent Rochas, Greta Poglia, Javier Bartolomei, Matthias Kirschner, Stefan Kaiser","doi":"10.1038/s41537-025-00596-z","DOIUrl":"10.1038/s41537-025-00596-z","url":null,"abstract":"<p><p>The hypoactivity of parvalbumin-containing interneurons (PV-interneurons) is a pathogenetic mechanism of schizophrenia according to the glutamatergic theory, and PV-interneurons are necessary for the generation of EEG/MEG gamma-frequencies (30-100 Hz). The present study aims to a literature synthesis on resting-state gamma-frequency changes in patients with schizophrenia vs healthy controls, and to examine the relationship between these changes and severity of symptoms. A protocol was enregistered in PROSPERO and a systematic search was conducted in PubMed, PsycINFO and Cochrane Database of Systematic Reviews, following PRISMA guidelines. An exploratory metanalysis was realized. Out of 1391 records, 43 were included for a qualitative synthesis (N = 2133 [11-185], females 37.4%, age 33.9 ± 9.2). Results on power spectra were heterogeneous: in 12 studies gamma power was increased, involving the whole brain (N = 3), multiple regions (N = 6) or only frontal (N = 1), central (n = 1) and temporal (N = 1) areas; in 3 studies gamma power was reduced, involving multiple areas (N = 2) or the right temporal region (N = 1); one study revealed mixed results and 13 studies showed no differences. The meta-analysis on 4 studies (N = 211) showed non-significant differences between patients and controls and a large heterogeneity. The functional connectivity picture consists of sparse patterns of decreases and/or increases, widespread to multiple regions. Relationships emerged between gamma power and connectivity and severity of psychotic and cognitive symptoms. Theta-gamma coupling was increased in patients, with limited evidence for other changes in phase-amplitude coupling. Resting-state gamma-frequencies alterations in schizophrenia were inconsistent across studies; the heterogeneity of patients and methods could partially explain this outcome.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"48"},"PeriodicalIF":3.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating large language models against manual information extraction from case reports of drug-induced parkinsonism in patients with schizophrenia spectrum and mood disorders: a proof of concept study.","authors":"Sebastian Volkmer, Alina Glück, Andreas Meyer-Lindenberg, Emanuel Schwarz, Dusan Hirjak","doi":"10.1038/s41537-025-00601-5","DOIUrl":"10.1038/s41537-025-00601-5","url":null,"abstract":"<p><p>In this proof of concept study, we demonstrated how Large Language Models (LLMs) can automate the conversion of unstructured case reports into clinical ratings. By leveraging instructions from a standardized clinical rating scale and evaluating the LLM's confidence in its outputs, we aimed to refine prompting strategies and enhance reproducibility. Using this strategy and case reports of drug-induced Parkinsonism, we showed that LLM-extracted data closely align with clinical rater manual extraction, achieving an accuracy of 90%.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"47"},"PeriodicalIF":3.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common and unique white matter fractional anisotropy patterns in patients with schizophrenia with medication-resistant auditory verbal hallucinations: a retrospective tract-based spatial statistics study.","authors":"Chuanjun Zhuo, Chao Li, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang, Lina Wang","doi":"10.1038/s41537-025-00597-y","DOIUrl":"10.1038/s41537-025-00597-y","url":null,"abstract":"<p><p>Auditory verbal hallucinations (AVHs) are experienced by the majority of patients with schizophrenia and are often resistant to treatment with antipsychotic agents. White matter (WM) tract abnormalities are associated with AVH treatment efficacy. Using a retrospective design, 115 patients with schizophrenia with AVHs, 48 with medication-resistant AVHs and 67 with treatable AVHs, and 70 healthy controls (HCs) were selected from the database of our cohort study for 5-year follow-up assessment. WM tract integrity was measured using tract-based spatial statistics (TBSS) at baseline and after 5 years of antipsychotic agent treatment. The fractional anisotropy (FA) value was used to demonstrate WM tract alterations in patients with schizophrenia with medication-resistant AVHs, in patients with schizophrenia with treatable AVHs, and in HCs. Our data demonstrated that medication-resistant patients showed significantly greater FA values in the corpus callosum (CC) fasciculus at baseline and in the corticospinal tract post-treatment compared to HCs, but the baseline difference in the CC fasciculus was no longer significant after 5 years of antipsychotic agent treatment. The medication-resistant AVH group exhibited greater FA values in the superior longitudinal fasciculus after 5 years of antipsychotic agent treatment. Compared to the HC group, the treatable AVH group exhibited significantly greater FA values in the visual radiation and CC after 5 years of antipsychotic agent treatment. In the medication-resistant and treatable groups, common WM tract abnormalities were noted, as greater FA values were observed in the CC group at baseline compared to the HC group. At the same time, distinct abnormalities were noted, as greater FA values were observed in the superior longitudinal fasciculus, which may contribute to medication-resistant AVHs, whereas abnormalities in the CC fasciculus may contribute to both treatable and medication-resistant AVHs. In the HCs, a decrease in FA values in the posterior CC was observed after 5 years of observation compared to baseline. In summary, patients with treatment-resistant AVHs with schizophrenia and patients with treatable AVHs with schizophrenia have common and distinct abnormalities in the WM tract.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"46"},"PeriodicalIF":3.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurobiology-based cognitive biotypes using multi-scale intrinsic connectivity networks in psychotic disorders.","authors":"Pablo Andrés-Camazón, Covadonga M Diaz-Caneja, Ram Ballem, Jiayu Chen, Vince D Calhoun, Armin Iraji","doi":"10.1038/s41537-025-00593-2","DOIUrl":"10.1038/s41537-025-00593-2","url":null,"abstract":"<p><p>Understanding neurobiology and developing effective interventions for cognitive dysfunction in psychotic disorders remain elusive. Insufficient knowledge about the biological heterogeneity of cognitive dysfunction hinders progress. We aimed to identify subgroups of patients with psychosis and distinct patterns of functional brain alterations related to cognition (cognitive biotypes). We analyzed B-SNIP consortium data (2 270 participants including participants with psychotic disorders, relatives, and controls, 55% females). We used reference-informed independent component analysis with the standardized and fully automated framework NeuroMark and the 100k multi-scale intrinsic connectivity networks (ICN) template to obtain subject-specific ICNs and whole-brain functional network connectivity (FNC). FNC features associated with cognitive performance were identified using multivariate joint analysis. K-means clustering identified patient subgroups based on these features. Two biotypes with different functional brain alteration patterns were identified. Relative to controls, biotype 1 exhibited hypoconnectivity in cerebellar-subcortical and somatomotor-visual networks and worse cognitive performance. Biotype 2 exhibited hyperconnectivity in somatomotor-subcortical networks, hypoconnectivity in somatomotor-high cognitive processing networks, and better-preserved cognitive performance. Demographic, clinical, cognitive, and FNC characteristics of biotypes were consistent in discovery and replication sets and in relatives. 76.56% of relatives were assigned to a psychosis biotype, of those, 70.12% were to the same biotype as their affected family members. These findings suggest two distinctive psychosis-related cognitive biotypes with differing functional brain patterns shared with their relatives. Instead of traditional diagnosis, patient stratification based on these biotypes may help optimize future research and identify biological targets for the treatment of cognitive dysfunction in psychosis.</p>","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"45"},"PeriodicalIF":3.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.","authors":"Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, Howard H Hassman, Rishi Kakar, David P Walling, Leslie Citrome, Haiyuan Zhu, Andrew C Miller, Stephen K Brannan","doi":"10.1038/s41537-025-00595-0","DOIUrl":"10.1038/s41537-025-00595-0","url":null,"abstract":"","PeriodicalId":74758,"journal":{"name":"Schizophrenia (Heidelberg, Germany)","volume":"11 1","pages":"44"},"PeriodicalIF":3.0,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}